A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Adalimumab (Primary) ; Lutikizumab (Primary) ; Lutikizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Horizon
- Sponsors AbbVie
Most Recent Events
- 28 Feb 2025 Planned End Date changed from 1 Apr 2027 to 1 Apr 2028.
- 28 Feb 2025 Planned primary completion date changed from 1 Apr 2027 to 1 Apr 2028.
- 16 Jan 2025 Planned End Date changed from 23 Apr 2027 to 1 Apr 2027.